Dr Reddys Laboratories Ltd Share Price – NSE  / BSE

Pharmaceuticals, Mid Cap

Dr Reddys Laboratories has received reaffirmation in credit rating for bank facilities aggregating Rs 2,000 crore at ICRA AA+; Stable.

Powered by Capital Market - Live News

Dr Reddys Laboratories Ltd is up for a third straight session in a row. The stock is quoting at Rs 1387.8, up 2.41% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.42% on the day, quoting at 23849.94921875. The Sensex is at 78785.09, up 0.4%. Dr Reddys Laboratories Ltd has added around 16.43% in last one month.

Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has added around 5.77% in last one month and is currently quoting at 22712.55, up 1.19% on the day. The volume in the stock stood at 21.03 lakh shares today, compared to the daily average of 26.64 lakh shares in last one month.

The benchmark January futures contract for the stock is quoting at Rs 1393.95, up 2.57% on the day. Dr Reddys Laboratories Ltd is up 18.44% in last one year as compared to a 9.51% gain in NIFTY and a 36.31% gain in the Nifty Pharma index.

The PE of the stock is 23.51 based on TTM earnings ending September 24.

Powered by Capital Market - Live News

According to the exchange filing, the subsidiary was officially established on 20 December 2024. The company disclosed that the delay in the announcement was due to the late receipt of information from the newly incorporated subsidiary. Dr Reddy's Finland Oy is a step-down wholly-owned subsidiary of the company.

The primary purpose of incorporating Dr. Reddy's Finland Oy is to engage in the healthcare and pharmaceutical sectors, including the general marketing, sales, and promotion of medical devices, as well as providing marketing and consulting services for these products. The business of Dr. Reddy's Finland Oy is in line with the main line of business of the company.

As Dr. Reddy’s Finland Oy is promoted by DRSA, it is considered a related party of Dr. Reddy’s Laboratories.

Dr Reddy's Labs is engaged in providing medicines. The firm operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI) and proprietary products.

The company’s consolidated net profit declined 15.3% to Rs 1,255.70 crore despite of 16.5% jump in revenue from operations to Rs 8,016.10 crore in Q2 FY25 over Q2 FY24.

The scrip rose 0.77% to Rs 1,351.15 on the BSE.

Powered by Capital Market - Live News

Dr Reddys Laboratories will hold a meeting of the Board of Directors of the Company on 23 January 2025.

Powered by Capital Market - Live News